Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Ulonivirine on Methadone Pharmacokinetics
NCT07595263Phase 1Recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2026
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ulonivirine in human immunodeficiency virus infection (HIV), sponsored by Merck & Co. Primary endpoints: Dose-Normalized Area Under the Plasma Concentration Time Curve From 0-24 Hours Postdose of R-Methadone and Dose-Normalized Area Under the Plasma Concentration Time Curve From 0-24 Hours Postdose of S-Methadone. Started Aug 2026; status: recruiting.
02
Drugs
ulonivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07595263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07595263.